AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 239907 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30
Study 239907 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorazepate
Number of subjects: 30
Study 239907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31808947 — intervention group
Group type: COMPARATOR
Intervention: 0.5% NaOCl
Number of subjects: 298
Study 31808947 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% NaOCl
Number of subjects: 298
Study 27620623 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Checkup (FCU) intervention
Number of subjects: 731
Study 27620623 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 731
Study 25467591 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) with ribavirin for 12 weeks
Number of subjects: 253
Study 25467591 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) with ribavirin for 18 weeks
Number of subjects: 253
Study 25467591 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) without ribavirin for 12 weeks
Number of subjects: 253
Study 25467591 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 253
Study 23242004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg once daily for 5 days)
Number of subjects: 12
Study 23242004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21103938 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day terbinafine
Number of subjects: 304
Study 21103938 — intervention group
Group type: COMPARATOR
Intervention: 100 mg/day itraconazole
Number of subjects: 304
Study 19844077 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, 2-hour educational programme conducted by a dermatologist or a dermatologist and a psychologist
Number of subjects: 123
Study 19844077 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, 2-hour educational programme
Number of subjects: 123
Study 17080254 — intervention group
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (LAC), n=13
Number of subjects: 24
Study 17080254 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=11
Number of subjects: 24
Study 15271737 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with fentanyl 10 microg
Number of subjects: 60
Study 15271737 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with fentanyl 20 microg
Number of subjects: 60
Study 15271737 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with fentanyl 30 microg
Number of subjects: 60
Study 15271737 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with fentanyl 40 microg
Number of subjects: 60
Study 11711355 — intervention group
Group type: EXPERIMENTAL
Intervention: Abarelix 100 mg
Number of subjects: 269
Study 11711355 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate 7.5 mg
Number of subjects: 269
Study 9155219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepackaged diet plan
Number of subjects: 560
Study 9155219 — intervention group
Group type: COMPARATOR
Intervention: Self-selected American Heart Association Step 1 and Step 2 diets
Number of subjects: 560
Study 7957455 — intervention group
Group type: EXPERIMENTAL
Intervention: microencapsulated potassium chloride tablet (MET)
Number of subjects: 18
Study 7957455 — intervention group
Group type: COMPARATOR
Intervention: potassium chloride solution (PS)
Number of subjects: 18
Study 7957455 — intervention group
Group type: COMPARATOR
Intervention: microencapsulated potassium chloride capsules (MEC)
Number of subjects: 18
Study 3678046 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (1.84% delta 9-THC)
Number of subjects: 12
Study 3678046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31563875 — intervention group
Group type: EXPERIMENTAL
Intervention: q‐FPs measured by dual‐photon microscopy
Number of subjects: 344
Study 31563875 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline q‐FPs
Number of subjects: 344
Study 31563875 — intervention group
Group type: COMPARATOR
Intervention: q‐FPs and histological scoring
Number of subjects: 344
Study 31170412 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED plus 50% of calories from formula (Modulen, Nestlé) for 6 weeks followed by CDED with 25% PEN from weeks 7 to 12 (n = 40)
Number of subjects: 74
Study 31170412 — intervention group
Group type: COMPARATOR
Intervention: EEN for 6 weeks followed by a free diet with 25% PEN from weeks 7 to 12 (n = 38)
Number of subjects: 74
Study 27820922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus Rituximab (B+R)
Number of subjects: 45
Study 26521770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 481
Study 26521770 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 481
Study 26521770 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 481
Study 26521770 — intervention group
Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC) alone
Number of subjects: 481
Study 24179977 — intervention group
Group type: EXPERIMENTAL
Intervention: SurfLink-treated titanium dental implants
Number of subjects: 23
Study 24179977 — intervention group
Group type: COMPARATOR
Intervention: Untreated control titanium dental implants
Number of subjects: 23
Study 24179977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SurfLink and control)
Number of subjects: 23
Study 22008390 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UFH (100 units kg(‐1) bolus, followed by 20 units kg h(‐1) continuous infusion)
Number of subjects: 227
Study 22008390 — intervention group
Group type: COMPARATOR
Intervention: Low-dose UFH (50 units kg(‐1) bolus)
Number of subjects: 227
Study 22008390 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UFH
Number of subjects: 227
Study 22008390 — intervention group
Group type: COMPARATOR
Intervention: Low-dose UFH
Number of subjects: 227
Study 19428087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic plexus block with 2 mL of 2% lidocaine
Number of subjects: 80
Study 19428087 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic nerve block (PPNB) with 2 mL of 2% lidocaine
Number of subjects: 80
Study 16716214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (100 mg daily for 5 days)
Number of subjects: 72
Study 16716214 — intervention group
Group type: COMPARATOR
Intervention: Medium dose aspirin (325 mg daily for 5 days)
Number of subjects: 72
Study 16716214 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin vs Medium dose aspirin
Number of subjects: 72
Study 14960530 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPSS alone (group 1)
Number of subjects: 79
Study 14960530 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPSS plus variceal band ligation (VBL) (group 2)
Number of subjects: 79
Study 14960530 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPSS plus VBL (group 2)
Number of subjects: 79
Study 11729022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 60
Study 11729022 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 60
Study 9389342 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTED system for sample preparation prior to HPLC
Number of subjects: 0
Study 7906473 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 5-6 hours before surgery
Number of subjects: 45
Study 7906473 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 12 hours before surgery
Number of subjects: 45
Study 7906473 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 24 hours before surgery
Number of subjects: 45
Study 7906473 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 48 hours before surgery
Number of subjects: 45
Study 7906473 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol (0.5%) administered 4 hours before surgery into the contralateral eye
Number of subjects: 45
Study 2886529 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of 500 mg metronidazole
Number of subjects: 440
Study 2886529 — intervention group
Group type: COMPARATOR
Intervention: Zero, two, three, six, or twenty-one doses of metronidazole
Number of subjects: 440
Study 29142012 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter interatrial shunt device (IASD)
Number of subjects: 44
Study 29142012 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 44
Study 27203272 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision support intervention using pamphlet and video decision aids for DT LVAD
Number of subjects: 168
Study 27203272 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 168
Study 25421542 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid administered once during preoperative hormonal therapy with letrozole for 24 weeks
Number of subjects: 0
Study 25421542 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 22401913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogen (0.625 mg per day)
Number of subjects: 10739
Study 22401913 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10739
Study 20885291 — intervention group
Group type: EXPERIMENTAL
Intervention: Scvo2-guided fluid therapy (crystalloid infusion 100 ml/h, bolus of 3 ml/kg hydroxyethyl starch if Scvo2 < 75%)
Number of subjects: 241
Study 20885291 — intervention group
Group type: COMPARATOR
Intervention: Traditional fluid regimen (crystalloid 800 ml/h, extra fluid for clinical signs of hypovolemia)
Number of subjects: 241
Study 18523025 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 276
Study 18523025 — intervention group
Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 276
Study 17138193 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial nerve injection (group RAD)
Number of subjects: 90
Study 17138193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar nerve injection (group ULN)
Number of subjects: 90
Study 14732882 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemotherapy regimens combining IL‐2, IFN‐alpha and chemotherapy
Number of subjects: 0
Study 14732882 — intervention group
Group type: COMPARATOR
Intervention: Cytokines alone (IL‐2 as a single agent or in combination with IFN‐alpha)
Number of subjects: 0
Study 14732882 — intervention group
Group type: COMPARATOR
Intervention: Biotherapy alone
Number of subjects: 0
Study 14732882 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 14732882 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy alone with additions (histamine or vaccines to IL‐2)
Number of subjects: 0
Study 10761967 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-g ginseng taken 40 minutes before glucose challenge
Number of subjects: 19
Study 10761967 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-g ginseng taken together with glucose challenge
Number of subjects: 19
Study 10761967 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-g ginseng taken before glucose challenge
Number of subjects: 19
Study 10761967 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 19
Study 8672407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-replaced meal (3305 kJ, 54.6 g SPE, 24 g fat)
Number of subjects: 0
Study 8672407 — intervention group
Group type: COMPARATOR
Intervention: Control meal (5192 kJ, 73.2 g fat)
Number of subjects: 0
Study 8672407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-replaced meal
Number of subjects: 0
Study 1599343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic intervention (weight reduction, sodium restriction, increased physical activity) consisting of eight weekly group sessions and two individual sessions followed by four monthly group sessions.
Number of subjects: 56
Study 1599343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 56
Study 1599343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic intervention (weight reduction, sodium restriction, increased physical activity).
Number of subjects: 56
Study 6532149 — intervention group
Group type: EXPERIMENTAL
Intervention: Response prevention treatment
Number of subjects: 39
Study 6532149 — intervention group
Group type: COMPARATOR
Intervention: Rapid smoking comparison treatment
Number of subjects: 39
Study 30616899 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching care (CC) with weekly phone calls for 3 months
Number of subjects: 8
Study 30616899 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) with one day of therapeutic education and one phone call
Number of subjects: 8
Study 30092590 — intervention group
Group type: EXPERIMENTAL
Intervention: IRE plus allogenic NK cells (IRE‐NK)
Number of subjects: 40
Study 30092590 — intervention group
Group type: COMPARATOR
Intervention: Simple IRE
Number of subjects: 40
Study 27670796 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter closure of PDA using the standard technique (group 1)
Number of subjects: 112
Study 27670796 — intervention group
Group type: COMPARATOR
Intervention: Catheter closure of PDA using an exclusive venous approach (group 2)
Number of subjects: 112
Study 24786935 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 244
Study 24786935 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (self-administered)
Number of subjects: 244
Study 24786935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 244
Study 22462640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D levels) at 24-26 weeks of gestation
Number of subjects: 697
Study 22462640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D < 50 nmol/l) at 24-26 weeks of gestation
Number of subjects: 697
Study 22462640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D levels) at 12-18 weeks of gestation
Number of subjects: 697
Study 20448031 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training of the plantar flexor muscles (15 sessions of unilateral mainly eccentric plantar flexor exercise over a 5‐wk period)
Number of subjects: 20
Study 20448031 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training of the plantar flexor muscles
Number of subjects: 20
Study 20448031 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 20
Study 17097834 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT)
Number of subjects: 227
Study 17097834 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 227
Study 16049121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour walk in natural surroundings
Number of subjects: 33
Study 16049121 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 33
Study 16049121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and nonintervention)
Number of subjects: 33
Study 12861790 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep diaphragmatic breathing technique
Number of subjects: 272
Study 12861790 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention technique
Number of subjects: 272
Study 12861790 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific technique mentioned)
Number of subjects: 272
Study 10394524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical assisted hatching (AH)
Number of subjects: 0
Study 10394524 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8878217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms Engerix-B vaccine
Number of subjects: 153
Study 8878217 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms Engerix-B vaccine
Number of subjects: 153
Study 2049750 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus prednisolone (PRDLN) (5 mg twice daily)
Number of subjects: 326
Study 2049750 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) (10 mg twice daily) plus placebo
Number of subjects: 326
Study 6504421 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 70
Study 6504421 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 70
Study 30723140 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus Alpelisib (2.5 mg/day letrozole with 300 mg/day alpelisib for 24 weeks)
Number of subjects: 257
Study 30723140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 24 weeks)
Number of subjects: 257
Study 30723140 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus Alpelisib
Number of subjects: 257
Study 30723140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 27654902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation + Supported Employment (CR + SE)
Number of subjects: 111
Study 27654902 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Services (TVS)
Number of subjects: 111
Study 26271753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble CPAP (B)
Number of subjects: 125
Study 26271753 — intervention group
Group type: COMPARATOR
Intervention: Flow Driver CPAP (FD)
Number of subjects: 125
Study 25143506 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric glenosphere
Number of subjects: 50
Study 25143506 — intervention group
Group type: COMPARATOR
Intervention: Eccentric glenosphere
Number of subjects: 50
Study 25143506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 22623022 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pill
Number of subjects: 141
Study 19389019 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U of botulinum toxin-A (BTX-A)
Number of subjects: 34
Study 19389019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17931925 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 65
Study 17931925 — intervention group
Group type: COMPARATOR
Intervention: 1.8 mL 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 65
Study 17931925 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bupivacaine and lidocaine
Number of subjects: 65
Study 15826236 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth pursuit eye movements
Number of subjects: 0
Study 15826236 — intervention group
Group type: EXPERIMENTAL
Intervention: Items stabilized on the retina moving with the pursuit target
Number of subjects: 0
Study 15826236 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniature items presented on the pursuit target
Number of subjects: 0
Study 15826236 — intervention group
Group type: COMPARATOR
Intervention: Smooth pursuit
Number of subjects: 0
Study 15826236 — intervention group
Group type: COMPARATOR
Intervention: Eye fixation
Number of subjects: 0
Study 11339921 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy (LAVH)
Number of subjects: 80
Study 11339921 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 80
Study 11339921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 9462439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg iv tds for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days
Number of subjects: 628
Study 9462439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg iv bd for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days
Number of subjects: 628
Study 8170877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin and nitroglycerin (GTN) at a constant dose of 16.6 micrograms/minute
Number of subjects: 50
Study 8170877 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin and isosorbide dinitrate at a constant dose of 33.3 micrograms/minute
Number of subjects: 50
Study 8170877 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received identical doses of heparin
Number of subjects: 50
Study 2947874 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol maleate 0.5%
Number of subjects: 14
Study 2947874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29474893 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized bronchodilator dosing
Number of subjects: 51
Study 29474893 — intervention group
Group type: COMPARATOR
Intervention: Fixed bronchodilator dosing
Number of subjects: 51
Study 29474893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 26105554 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week progressive resistance training (PRT)
Number of subjects: 35
Study 26105554 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (acute effect)
Number of subjects: 35
Study 26105554 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 24769306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily for 8 weeks
Number of subjects: 80
Study 24769306 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 80
Study 23875907 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulation group (catheter inversion technique for concave aspect, prominent Eustachian ridge, steep angle of the CTI)
Number of subjects: 446
Study 23875907 — intervention group
Group type: COMPARATOR
Intervention: Nonmodulation group (conventional strategy)
Number of subjects: 446
Study 21397720 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine with GM-CSF
Number of subjects: 0
Study 21397720 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine without GM-CSF
Number of subjects: 0
Study 21397720 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline progenitor cell frequency
Number of subjects: 0
Study 21397720 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline monocyte frequency
Number of subjects: 0